News
Shares of Verve Therapeutics skyrocketed 75% Tuesday morning after Eli Lilly announced that it would acquire the gene-editing startup for about $1.3 billion.
We came across a bullish thesis on Verve Therapeutics, Inc. on Stock Region Research’s Substack by Stock Region. In this ...
Verve Therapeutics licensed some of the base-editing technology VERVE-101 is based on from Beam Therapeutics. In October, Verve's collaboration partner, Eli Lilly, handed Beam $250 million upfront ...
2h
Zacks Investment Research on MSNEli Lilly vs. Merck: Which Drug Giant Appears Better Poised Today?Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...
Verve Therapeutics’ stock was rallying by a record 80% on Eli Lilly’s premium purchase price for the drug-development company.
Verve Therapeutics (NASDAQ: VERV) is up 16.5% for the week. The biotech stock, which was as low as $41.52 a share on Monday, climbed as high as $48.39 by Thursday. For a relatively new stock (it ...
Verve Therapeutics, a next-generation cardiovascular company, today announced the presentation of new preclinical proof-of-concept data in non-human p ...
Since reporting some early-stage clinical data from one of its gene editing programs on Nov. 12, share prices of Verve Therapeutics (VERV-2.29%) are down 42%. But contrary to what you may be ...
Verve Therapeutics, Inc. (NASDAQ:VERV) is a Boston, Mass., based biotech that IPO'd in June 2021, raising ~$307m via the issuance of 16.1m shares priced at $19 per share.
Beam is selling Lilly the opt-in rights to a trio of candidates covered by an agreement it signed with Verve Therapeutics in 2019 for $200 million in upfront cash, ...
Why Verve Therapeutics stock tanked. There were no issues on the safety front that clearly indicate trouble ahead for VERVE-101 but the initial portion of the study was less than flawless.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results